Department of Immunopathology and Cancer Biomarkers, CRO National Cancer Institute, I.R.C.C.S, via Gallini, 2, 33080, Aviano, Italy.
Department of Surgical Oncology, CRO National Cancer Institute, I.R.C.C.S, via Gallini, 2, 33080, Aviano, Italy.
World J Surg Oncol. 2018 Jun 19;16(1):115. doi: 10.1186/s12957-018-1410-x.
Local excision (LE) is currently one of the most effective methods used in cases of large benign polyps, not suitable for endoscopic treatment, or early-stage neoplasms. LE is also alternative to anterior rectal resection in selected patients suffering from major comorbidities and limits for major abdominal procedure. Furthermore, LE results in less pain, reduced impact on bowel function, shorter duration of hospital stay, and lower rates of morbidity, mortality and stoma creation. In particular, early data on transanal minimally invasive surgery (TAMIS) are promising, but they come from single centre case series related to small groups of patients and more data are needed to draw a final conclusion on the safety of this novel approach for transanal resection.
A 62-year-old woman, following a positive faecal occult blood test and with unremarkable medical history, was admitted to hospital for excision of a large flat neoplastic lesion. Endoscopic biopsy demonstrated a tubular adenoma with high-grade dysplasia and was decided to proceed with surgical excision by TAMIS. After surgery, short-term outcomes revealed prolonged activated partial thromboplastin time, undetectable factor XII activity, fever, and partial dehiscence of rectal wall defect suture. Cross-mixing studies of patient plasma show no correction in either the immediate or incubated activated partial thromboplastin time, indicating the presence of an acquired factor XII inhibitor. Activated partial thromboplastin time and factor XII improved in the following weeks without any specific therapy in addition to antibiotic therapy.
This is the first report in which acquired inhibitor of coagulation factor XII is associated with a specific surgical procedure. This case has shown how trans-anal excision of rectal lesions, even when performed by minimally invasive means such as in case of TAMIS, is not free of complications. We consider the acute infection, resulting from early dehiscence of the suture, the trigger in an abnormal immune response, and inhibitor development.
局部切除术(LE)是目前治疗大型良性息肉、不适合内镜治疗或早期肿瘤的最有效方法之一。对于患有重大合并症和进行大腹部手术限制的患者,LE 也是直肠前切除术的替代方法。此外,LE 导致的疼痛较少,对肠道功能的影响较小,住院时间较短,发病率、死亡率和造口形成率较低。特别是,经肛门微创外科(TAMIS)的早期数据很有前景,但这些数据来自于与小患者群体相关的单中心病例系列,需要更多的数据来得出关于这种经肛门切除新方法安全性的最终结论。
一位 62 岁女性,粪便潜血试验阳性,无明显病史,因切除大型平坦新生物病变而入院。内镜活检显示管状腺瘤伴高级别异型增生,决定行 TAMIS 手术切除。手术后,短期结果显示活化部分凝血活酶时间延长、因子 XII 活性不可检测、发热和直肠壁缺损缝合部分裂开。患者血浆的交叉混合研究显示即时或孵育的活化部分凝血活酶时间均无纠正,表明存在获得性因子 XII 抑制剂。除了抗生素治疗外,在接下来的几周内,活化部分凝血活酶时间和因子 XII 得到改善,没有任何特定的治疗。
这是首例报道获得性凝血因子 XII 抑制剂与特定手术相关的病例。本病例表明,即使通过 TAMIS 等微创手段进行经肛门直肠病变切除,也并非没有并发症。我们认为,早期缝合裂开引起的急性感染是异常免疫反应和抑制剂发展的触发因素。